Malignancy, Male Reproductive System without CC/MCC DRG Reimbursement

DRG 724 pertains to inpatient stays for malignant neoplasms of the male reproductive system without Complications or Comorbidities or Major Complications or Comorbidities, covering common procedures and treatment-related hospital care. Correct assignment of this Diagnosis-Related Group is important because it determines the Medicare bundled payment for the episode of care and influences hospital reimbursement.

DRG 724 Overview

DRG 724 covers hospital admissions for malignant neoplasms of the male reproductive system when there are no Complications or Comorbidities and no Major Complications or Comorbidities. This includes primary treatments and procedures related to prostate, testicular, penile, and other male reproductive malignancies without additional documented complexity. It matters for Medicare payment because the assigned Diagnosis-Related Group determines the bundled inpatient reimbursement and affects hospital revenue for these cancer-related admissions. Accurate coding of diagnoses and procedures is essential to ensure the correct Diagnosis-Related Group assignment.

Trials evaluating surgical approaches and perioperative care for localized male genitourinary cancers: randomized or prospective cohort studies comparing different surgical techniques (e.g., radical prostatectomy variations or partial vs total orchiectomy when applicable), anesthesia protocols, and intraoperative blood management in patients hospitalized primarily for cancer-directed surgery. These studies enroll patients admitted for operative management of male reproductive malignancies, often focusing on short-term surgical complications, length of stay, and readmission rates, and are relevant to providers optimizing operative risk and to payers because perioperative resource use and complication-driven costs are concentrated during the inpatient episode.
Comparative effectiveness and sequencing studies of systemic and adjuvant therapies in the non-acute inpatient setting: observational registries and pragmatic trials examining outcomes of different adjuvant treatment strategies or timing of systemic therapy initiation after surgery for high-risk or locally advanced male reproductive cancers. These studies target patients who require inpatient stays for therapy initiation, management of treatment-related toxicities, or complex multimodal care coordination, informing clinicians on which approaches yield better survival, toxicity profiles, or reduced inpatient utilization, and informing payers about downstream cost implications tied to chosen treatment pathways.
Post-discharge outcomes, rehabilitation, and survivorship cohort studies focused on functional recovery and healthcare utilization: prospective observational studies following patients hospitalized for malignancies of the male reproductive system to measure urinary, sexual, and psychosocial functional outcomes, rates of readmission or emergency department use, and long-term outpatient care needs. These investigations enroll the typical inpatient population transitioning to outpatient care and are important for providers and payers because they identify drivers of post-discharge resource use, opportunities to reduce preventable readmissions, and interventions that may improve value across the continuum of care.

Trials evaluating surgical approaches and perioperative care for localized male genitourinary cancers: randomized or prospective cohort studies comparing different surgical techniques (e.g., radical prostatectomy variations or partial vs total orchiectomy when applicable), anesthesia protocols, and intraoperative blood management in patients hospitalized primarily for cancer-directed surgery. These studies enroll patients admitted for operative management of male reproductive malignancies, often focusing on short-term surgical complications, length of stay, and readmission rates, and are relevant to providers optimizing operative risk and to payers because perioperative resource use and complication-driven costs are concentrated during the inpatient episode.
Comparative effectiveness and sequencing studies of systemic and adjuvant therapies in the non-acute inpatient setting: observational registries and pragmatic trials examining outcomes of different adjuvant treatment strategies or timing of systemic therapy initiation after surgery for high-risk or locally advanced male reproductive cancers. These studies target patients who require inpatient stays for therapy initiation, management of treatment-related toxicities, or complex multimodal care coordination, informing clinicians on which approaches yield better survival, toxicity profiles, or reduced inpatient utilization, and informing payers about downstream cost implications tied to chosen treatment pathways.
Post-discharge outcomes, rehabilitation, and survivorship cohort studies focused on functional recovery and healthcare utilization: prospective observational studies following patients hospitalized for malignancies of the male reproductive system to measure urinary, sexual, and psychosocial functional outcomes, rates of readmission or emergency department use, and long-term outpatient care needs. These investigations enroll the typical inpatient population transitioning to outpatient care and are important for providers and payers because they identify drivers of post-discharge resource use, opportunities to reduce preventable readmissions, and interventions that may improve value across the continuum of care.

OpenPayer

Summary & Overview

Malignancy, Male Reproductive System without CC/MCC: Inpatient Reimbursement Overview

DRG 724 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes